Renerve Limited · ASX:RNV
Renerve — Investor Presentation (May 2026)
21 slides from Renerve's investor presentation, May 8, 2026
Slide 1: Transforming Nerve Repair Through Science
ASX:RNV Transforming Nerve Repair Through Science ReNerve Company presentation | Quarterly webinar May 2026
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd Disclaimer: No representation or warranty, express or implied, is made by the Company that (Company) to provide general information about the Company. The information in this the material
Slide 3: Executive Summary
Executive Summary Summary Development of Novel Expanding Strong Sales & Nerve Repair & Product Portfolio Distribution Presence Regeneration Products ReNerve is developing a comprehensive 3 product ranges in the US market ReNerve has established logistics, portfolio of products for the nerve repair w
Slide 4: Executive Quarter Summary highlights
Executive Quarter Summary highlights ReNerve quartrly sales '23 to '26 Revenue up 79% $140,000.00 First $100K+ month March the first $100,000+ $120,000.00 month for ReNerve sales $100,000.00 $80,000.00 $60,000.00 Cash of $3.2M $40,000.00 Sales up to $132,000 for the $20,000.00 quarter and growing $0
Slide 5: Executive Quarter Summary highlights
Executive Quarter Summary highlights Regulatory & development milestones across the NervAlign® range • Additional regulatory approvals for NervAlign® Nerve Cuff in Hong Kong & Malaysia • Further progress in India for the NervAlign® Nerve Cuff approval • NervAlign® Nerve Guide Matrix enters Stage 3 o
Slide 6: Company Portfolio
Company Portfolio Product Product Commercial On Market R&D Development Development Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental ReNerve Company presentation | May 2026 6
Slide 7: Target Market
Target 2031 Market USD$6.0Bn USD$6.19Bn The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. Our Target Markets Global Nerve Repair Biomaterial Market Dermal and Amniotic Tissue 2025 Surgical Applications (
Slide 8: ReNerve’s Nerve Opportunity
ReNerve’s Nerve Opportunity Nerve Cuff Nerve Conduit Nerve Guide Matrix Bionic Nerve • Used on damaged or transected • Improved Nerve Cuff developed from • An ‘off-the-shelf’, ready to use nerve • An ‘off-the-shelf’, continuous nerve Product nerves with no gaps or gap closure scCO2 tissue, offering
Slide 9: Sales and Marketing Update
Sales and Marketing US Market Expanded Update Distribution Channels Robust Portfolio • Expanded to 21 distributors across the US • Full logistics, warehousing and invoicing in place • Distributors can sell the entire ReNerve product range • Will add additional to the network as products come to mark
Slide 10: Ex-US Sales & Marketing
Ex-US Sales & Marketing Sales Highlights ReNerve Distribution Final stages of approval process in India India Asia MIDDLE EAST Seeking multiple approval applications across Asia Significant potential due to population On market in Hong Kong, Malaysia Entered into exclusive partnership and open marke
Slide 11: Nerve Cuff
Wound Care Overview and Information Nerve Cuff RN-SM-TRN-012 Rev.0
Slide 12: Key Features
Key Features ReNerve’s “Align” 1 Product • Protects nerves during recovery post peripheral nerve Clinical Study repair • Great handling characteristics and absorbed within 6 Patient Results months 2 Definitive clinical study on using NervAlign Nerve Patient Benefit Cuff for nerve repair 120 patients
Slide 13: The “Align” Study
The “Align” Study Clinical Study on the NervAlign® Nerve Cuff Undertaking a definitive study in nerve repair following surgical neurolysis to show the benefit of protecting the nerve post nerve Comparison of Patient Pre & Post repair surgery. Surgery Pain Score 7.1 7.1 Study Design: Two patient coho
Slide 14: Product Development Pipeline
Wound Care Overview and Information Product Development Pipeline RN-SM-TRN-012 Rev.0
Slide 15: Product Development Pipeline
Product Development Pipeline Nerve Conduit and protector ranges Nerve ● Includes the Nerve cap conduit range ● Significant scale manufacturing this quarter ● 3 types of conduits to come to market In the commercial development Stage 3 of 4 Nerve FDA approval pathway confirmed guide matrix Next step G
Slide 16: Product Range
Wound Care Overview and Information Product Range RN-SM-TRN-012 Rev.0
Slide 17: Empliq Product Portfolio
Empliq Product Portfolio Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Description Single-layer amniotic membrane Double-layer amniotic membrane Placental allograft including amniotic Deep-layer dermal matrix allograft allograft membrane and chorion Clinical Value Natural barrier t
Slide 18: Executive Catalysts Summary CY26
Executive Catalysts Summary CY26 Continued focus on sales expansion with first direct sales reps now full-time Approval for the NervAlign® Nerve Cuff in India, a major market opportunity European approval submission, utilising the data from the 'Align' study Approval across additional south-east Asi
Slide 19: Value drivers for the next 12 months
Empliq products ranges Continue to expand into Value drivers for now in the US market Ex-US markets the next 12 months ● Complements the nerve products sales ● ● Establishing partners Ex-USA Pending approval in several ● Anticipating faster sales growth countries in 2026 through multiple products ●
Slide 20: Investment Highlights
Investment Highlights In Market Products Immediate Market Need Growing Market Nerve Cuff transitioned from R&D to Products promote nerve injury recovery and Nerve repair biomaterials and related markets commercial sales with 3 product lines in wound repair leading to faster patient are forecast to g
Slide 21: Contact Us
ReNerve Company presentation | May 2026 Contact Us ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia